Krystal Biotech Inc (KRYS)
Receivables turnover
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 102,227 | 56,573 | 9,365 | 809 | 809 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 542 | 1,125 | 1,342 | 1,515 |
| Receivables | US$ in thousands | 46,467 | 42,040 | 9,316 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | 2.20 | 1.35 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
March 31, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $102,227K ÷ $46,467K
= 2.20
The receivables turnover ratio for Krystal Biotech Inc has been showing an increasing trend over the past few quarters. As of March 31, 2024, the receivables turnover ratio stands at 2.20, indicating that the company collected its accounts receivable 2.20 times during the period.
This improvement in the receivables turnover ratio suggests that Krystal Biotech Inc is becoming more efficient in collecting its outstanding payments from customers. A higher turnover ratio is generally indicative of a shorter collection period and better management of accounts receivable.
Overall, the increasing trend in the receivables turnover ratio reflects positively on the company's liquidity and operational efficiency. It indicates that Krystal Biotech is effectively managing its accounts receivable, which can lead to improved cash flow and working capital management.
Peer comparison
Mar 31, 2024